Apollo Hospitals Q2 results: PAT rises 26% YoY to Rs 477 crore

Apollo Hospitals Enterprise reported another strong quarter of growth, with consolidated profit after tax (PAT) rising 26% year-on-year to Rs 477 crore in the September quarter (Q2FY26), driven by broad expansion in healthcare, diagnostics and digital healthcare.The company’s consolidated revenue grew 13% year-on-year to Rs 6,304 crore, supported by steady patient volumes and margin improvement in the hospital and retail healthcare segments.

Stable momentum in all core activities

Revenue from Healthcare Services (HCS) – Apollo’s hospital business – rose 9% year-on-year to Rs 3,169 crore, with occupancy improving to 69%. The company reported an EBITDA of Rs 781 crore for this segment, up 8% YoY, while PAT rose 13% YoY to Rs 410 crore, driven by efficiency gains and strong patient inflow for complex procedures.The Apollo Health and Lifestyle Ltd (AHLL) segment, which operates clinics and diagnostics, continued to grow, with revenue up 17% to Rs 474 crore and EBITDA improving 21% to Rs 50 crore.

Meanwhile, Apollo HealthCo, home to digital health platform Apollo 24|7 and the company’s pharmaceutical distribution business, posted revenues of Rs 2,661 crore, up 17% year-on-year, with EBITDA of Rs 110 crore. The gross merchandise value (GMV) of the platform stood at Rs 723 crore, underscoring Apollo’s growing digital footprint in healthcare.

Chairman Dr. Prathap C Reddy said the company’s continued investments in technology and innovation have helped strengthen patient care and drive operational efficiency. “We are proud to have touched over 200 million lives and earned trust in 185 countries. Our early adoption of the latest technology has led to over 51 lakh surgeries, 27,000 organ transplants and 22,000 robotic surgeries,” said Dr. Reddy. He added that Apollo was increasingly using AI-driven diagnostics and machine learning platforms. to personalize the treatment of cancer and cardiovascular disease patients. In the quarter, the company also introduced South Asia’s first AI-based music therapy at the Apollo Proton Cancer Center to improve the quality of life of cancer patients undergoing chemotherapy.

During the quarter, the Competition Commission of India (CCI) approved the company’s restructuring plan involving Apollo HealthCo, Keimed and Apollo Healthtech, paving the way for Apollo to move forward with its reorganization aimed at unlocking shareholder value.

The company also reiterated that investment intensity will continue to decline after heavy investments in recent years, even as it continues to expand its hospital and clinical capabilities.